期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 200, 期 3, 页码 353-357出版社
WILEY
DOI: 10.1111/bjh.18484
关键词
anti-D; anti-RhD; immune thrombocytopenia; ITP
类别
The report retrospectively reviews the use of IM Anti-D treatment in 74 adult patients, and concludes that it is an effective and safe treatment option for immune thrombocytopenia.
Intravenous Anti-Rhesus-D immunoglobulin (Anti-D) is a first-line treatment option for immune thrombocytopenia in non-splenectomised and RhD-positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti-D treatment in 74 adult patients between 1990 and 2018. We found that 73% of patients showed a response; almost all of them had complete responses (68.89%), and 26% achieved complete responses sustained at least 6 months after treatment discontinuation. No significant side effects were observed with no cases of acute haemolysis or anaemia reported. We conclude from this study that IM Anti-D is an effective and safe treatment for immune thrombocytopenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据